NCT02347345View on ClinicalTrials.gov

Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs

PHASE4CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

November 15, 2016

Primary Completion Date

November 15, 2016

Study Completion Date

November 15, 2016

Conditions
Hepatitis C
Interventions
DRUG

Harvoni (Fixed dose combination ledipasvir/sofosbuvir)

Harvoni (Fixed dose combination ledipasvir/sofosbuvir), one pill daily x 12 weeks

Trial Locations (1)

10021

Rockefeller University Hospital, New York

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Rockefeller University

OTHER

NCT02347345 - Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs | Biotech Hunter | Biotech Hunter